About Martin Vogelbaum
Form D filings for Ajax Therapeutics from 2019 to 2024 list Martin Vogelbaum as chief executive officer and director.
Martin Vogelbaum first appears on SEC filings in 2019.
Experience
This experience comes from SEC filings. The years are when the filings name Martin Vogelbaum in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Martin Vogelbaum works with at each company, as listed on that company's latest Form D.
Ajax Therapeutics, Inc. · Form D, May 13, 2024